XL-protein develops and commercializes its proprietary clinical-stage PASylation® technology to extend the in vivo half-life of biopharmaceuticals. The genetic fusion (or chemical conjugation) with conformationally disordered amino acid sequences composed of the three small residues Pro, Ala, and/or Ser ('PASylation') provides a simple means to attach a solvated biopolymer with large hydrodynamic volume to a therapeutic protein or peptide. This polypeptide adopts a bulky random coil structure, which significantly increases the size of the biopharmaceutical. By this way the typically rapid clearance of the biologically active component via kidney filtration, or in the eye, is retarded by 1-2 orders of magnitude, depending on the length of the PAS tag. Compared with other strategies to prolong the plasma half-life of biologics PASylation technology offers a genetically encoded biopolymer with precise definition which is biochemically inert while biodegradable in the body.
Company Details
- Employees
- 5
- Founded
- 2009
- Address
- Lise-Meitner-Strasse 30, Freising,d-85354,germany
- Phone
- +49 (0) 8161 53730-90
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- xl-protein.com
- Keywords
- Freiburg.
- HQ
- Freising
Xl-Protein Gmbh Questions
Xl-Protein Gmbh's helpline number is +49 (0) 8161 53730-90
Xl-Protein Gmbh's website is xl-protein.com
Xl-Protein Gmbh's LinkedIn profile is https://de.linkedin.com/company/xl-protein
Xl-Protein Gmbh has
5 employees.
View email and phone details for 5
employees at Xl-Protein Gmbh.
Xl-Protein Gmbh's industry is
Biotechnology Research
Xl-Protein Gmbh's top competitors are
Screensys Gmbh,
Eisbach Bio Gmbh,
Pieris Pharmaceuticals,
Isar Bioscience Gmbh,
Baseclick,
Biomagnetix,
Chromotek,
Bicoll,
Sitools Biotech Gmbh,
Rnatics.
Xl-Protein Gmbh's categories are Biotechnology Research
Xl-Protein Gmbh's founding year is 2009
